SEC Form 4 · accession 0001209191-17-020257
Ampio Pharmaceuticals, Inc. · AMPE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Macaluso
Officer — Chief Executive Officer · Director
Period of report
Mar 9, 2017
Accepted (ET)
Mar 13, 2017 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411906
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.81 | Mar 9, 2017 | A | 400,000 | A | — | Mar 9, 2027 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1133,333 shares subject to the Option will vest and become exercisable on each of January 9, 2018 and January 9, 2019 and 133,334 shares will vest and become exercisable on January 9, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date, and the terms under the Company's 2010 Stock Option and Incentive Plan and an employment agreement between the Reporting Person and the Issuer.